Search
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigational[L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy
Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.
Mivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnMivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...
Colistimethate
go.drugbank.com/drugs/DB01111ApprovedInvestigationalVet approvedColistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms.
Coagulation Factor IX (Recombinant)
go.drugbank.com/drugs/DB00100ApprovedIt has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. … IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as
Pork collagen
go.drugbank.com/drugs/DB14100ApprovedIt has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawn[L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with
Atracurium besylate
go.drugbank.com/drugs/DB00732ApprovedA non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate no...
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalas major side effects. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as
Propiverine
go.drugbank.com/drugs/DB12278ApprovedOAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].